Harmony Biosciences Holdings (HRMY) Total Debt (2019 - 2026)
Harmony Biosciences Holdings (HRMY) posted Total Debt of $158.8 million for Q1 2026, down 2.96% sequentially from $163.7 million in Q4 2025, and down 9.6% YoY from $175.7 million in Q1 2025.
Harmony Biosciences Holdings (HRMY) Total Debt (2019 - 2026) Analysis & Trends
Harmony Biosciences Holdings has reported Total Debt for 8 years, with the latest figure at $158.8 million in Q1 2026.
- Quarterly Total Debt fell 9.6% year-over-year to $158.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $158.8 million (down 9.6% YoY) and the FY2025 annual result came in at $163.7 million, down 8.7% from the prior year.
- Total Debt eased to $158.8 million in Q1 2026 per HRMY's latest filing, from $163.7 million in the prior quarter.
- Over five years, Total Debt peaked at $197.1 million in Q3 2023 and troughed at $158.8 million in Q1 2026.
- A 5-year average of $183.4 million and a median of $190.0 million in 2024 frame the typical range for Total Debt.
- The sharpest annual moves came in 2023 and 2026: Total Debt rose 2.82% in 2023, then declined 9.6% in 2026.
- Over 5 years, Total Debt stood at $191.6 million in 2022, then rose by 1.0% to $193.6 million in 2023, then dropped by 7.39% to $179.3 million in 2024, then slipped by 8.7% to $163.7 million in 2025, then dropped by 2.96% to $158.8 million in 2026.
- According to Business Quant data, Total Debt over the past three periods registered $158.8 million, $163.7 million, and $168.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.07 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.34 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Harmony Biosciences Holdings | 2.22 Bn | 1.41 Bn | 198.08 Mn | 153.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 153.96 Mn |
| Mar 31, 2026 | 158.81 Mn |
| Dec 31, 2025 | 163.66 Mn |
| Sep 30, 2025 | 168.51 Mn |
| Jun 30, 2025 | 172.10 Mn |
| Mar 31, 2025 | 175.68 Mn |
| Dec 31, 2024 | 179.27 Mn |
| Sep 30, 2024 | 182.85 Mn |
| Jun 30, 2024 | 186.42 Mn |
| Mar 31, 2024 | 190.00 Mn |
| Dec 31, 2023 | 193.57 Mn |
| Sep 30, 2023 | 197.13 Mn |
| Jun 30, 2023 | 191.49 Mn |
| Mar 31, 2023 | 191.56 Mn |
| Dec 31, 2022 | 191.65 Mn |
| Sep 30, 2022 | 191.73 Mn |
| Jun 30, 2022 | 191.81 Mn |
| Mar 31, 2022 | 191.90 Mn |
| Dec 31, 2021 | 191.98 Mn |
| Sep 30, 2021 | 192.07 Mn |